<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (AA) patients both present with symptoms of <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In many AA patients, these features are thought to result from an oligoclonal expansion of cytotoxic T-cells that destroy haematopoietic stem or progenitor cells </plain></SENT>
<SENT sid="2" pm="."><plain>This notion is supported by the observation that AA patients respond to immunosuppressive therapy </plain></SENT>
<SENT sid="3" pm="."><plain>A fraction of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients also respond well to immunosuppressive therapy suggesting a similar role for cytotoxic T-cells in the etiology of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, however the role of cytotoxic T-cells in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> remains unclear </plain></SENT>
<SENT sid="4" pm="."><plain>Mice that express a NUP98-HOXD13 (NHD13) transgene develop a <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> that closely mimics the human condition in terms of <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, ineffective hematopoiesis, and transformation to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="5" pm="."><plain>We followed a cohort of NHD13 mice lacking the Rag1 protein (NHD13/Rag1KO) to determine if the <z:mp ids='MP_0000726'>absence of lymphocytes</z:mp> might 1) delay the <z:hpo ids='HP_0003674'>onset</z:hpo> and/or diminish the severity of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, or 2) effect <z:e sem="disease" ids="C1608408" disease_type="Neoplastic Process" abbrv="">malignant transformation</z:e> and survival of the NHD13 mice </plain></SENT>
<SENT sid="6" pm="."><plain>No difference was seen in the <z:hpo ids='HP_0003674'>onset</z:hpo> or severity of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> between the NHD13 and NHD13/Rag1KO mice </plain></SENT>
<SENT sid="7" pm="."><plain>However, NHD13/Rag1KO mice had decreased survival and showed a trend toward increased incidence of transformation to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> compared to the NHD13 mice, suggesting protection from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> transformation by a modest immuno-surveillance effect </plain></SENT>
<SENT sid="8" pm="."><plain>In the absence of functional Tcrb signaling in the NHD13/Rag1KO T-cell <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, Pak7 was identified as a potential Tcrb surrogate survival signal </plain></SENT>
</text></document>